Prognostic value of transforming growth factor-beta in patients with colorectal cancer who undergo surgery: a meta-analysis
| Autor: | Yue Hu, Xu-jie Xi, Fengbin Liu, Shuilian Zhu, Tian-wen Liu, Zhuo-qun Chen, Lei Lian, Yi Wen, Yi-sheng Su, Xinlin Chen |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
TGF-β 0301 basic medicine Cancer Research medicine.medical_specialty Colorectal cancer MEDLINE lcsh:RC254-282 Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Asian People Transforming Growth Factor beta Surgical oncology Biomarkers Tumor Genetics Humans Medicine Proportional Hazards Models business.industry Proportional hazards model Incidence (epidemiology) Hazard ratio Prognosis lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Confidence interval Surgery Transforming growth factor-beta Meta-analysis 030104 developmental biology Oncology 030220 oncology & carcinogenesis Female Colorectal Neoplasms business Research Article |
| Zdroj: | BMC Cancer, Vol 17, Iss 1, Pp 1-11 (2017) BMC Cancer |
| ISSN: | 1471-2407 |
| Popis: | Background Transforming growth factor-beta (TGF-β) is associated with a higher incidence of distant metastasis and decreased survival. Whether TGF-β can be used as a prognostic indicator of colorectal cancer (CRC) remains controversial. Methods The Medline, EMBASE and Cochrane databases were searched from their inception to March 2016. The studies that focused on TGF-β as a prognostic factor in patients with CRC were included in this analysis. Overall survival (OS) and disease-free survival (DFS) were analysed separately. A meta-analysis was performed, and hazard ratios (HR) with 95% confidence intervals (CI) were calculated. Results Twelve studies were included in the analysis, of which 8 were used for OS and 7 for DFS. In all, 1622 patients with CRC undergoing surgery were included. Combined HRs suggested that high expression of TGF-β had a favourable impact on OS (HR = 1.68, 95% CI: 1.10–2.59) and DFS (HR = 1.11, 95% CI: 1.03–1.19) in CRC patients. For OS, the combined HRs of Asian studies and Western studies were 1.50 (95% CI: 0.61–3.68) and 1.80 (95% CI: 1.33–2.45), respectively. For DFS, the combined HRs of Asian studies and Western studies were 1.42 (95% CI: 0.61–3.31) and 1.11 (95% CI: 1.03–1.20), respectively. Conclusions This meta-analysis demonstrates that TGF-β can be used as a prognostic biomarker for CRC patients undergoing surgery, especially for CRC patients from Western countries. Electronic supplementary material The online version of this article (doi:10.1186/s12885-017-3215-7) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|